Intec Pharma Ltd. (NASDAQ:NTEC) has received an average rating of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.25.

NTEC has been the topic of a number of research analyst reports. Oppenheimer Holdings, Inc. set a $15.00 price target on Intec Pharma and gave the company a “buy” rating in a report on Friday. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. CIBC restated an “outperform” rating and issued a $15.00 target price (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on Intec Pharma and gave the company a “buy” rating in a research note on Thursday, August 10th.

An institutional investor recently raised its position in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. raised its position in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 522,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned approximately 3.80% of Intec Pharma worth $2,977,000 at the end of the most recent quarter. 16.41% of the stock is currently owned by institutional investors.

Intec Pharma (NASDAQ NTEC) opened at 8.40 on Monday. The stock’s market capitalization is $115.40 million. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80. The stock has a 50 day moving average price of $8.61 and a 200-day moving average price of $8.61.

WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/16/intec-pharma-ltd-ntec-given-average-recommendation-of-buy-by-brokerages.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.